China

Chengdu Kanghong Pharmaceutical Group

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

China's Kanghong Pharma Hits Limit Down as France Stops Trials of Ophthalmic Drug

Lead Product(s): Conbercept

Therapeutic Area: Ophthalmology Product Name: KHB-1802

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 29, 2021

Details:

No reasons for the suspension of project KHB-1802 were given nor was there any mention of whether it will be resumed in the near future nor whether it will affect the registration of the drug in France.

Luye Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

Boan Biotech Completes First Patient Dosing in Phase Ⅲ Clinical Trial for LY09004, Multiple R&D Projects Under Intensive Development

Lead Product(s): Aflibercept

Therapeutic Area: Ophthalmology Product Name: LY09004

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 08, 2021

Details:

LY09004 is a recombinant human vascular endothelial growth factor receptor antibody fusion protein ophthalmic injection (strength 11.12mg(0.278ml)/vial).